Nuvalent Inc

NUVL is in a Stage 4 decline with sequential lower highs and lower lows and is trading below all major EMAs and moving averages. The active Support Failure and Lower Highs & Lower Lows patterns confirm supply dominance and ongoing downtrend. With no signs of stabilization, EMA repair, or volatility contraction, selling into rallies at the 9EMA/20EMA and 50DMA is the preferred execution posture now.

• ↑FDA Priority Review for neladalkib and zidesamtinib with PDUFAs in 2026.
• ↑GSK’s $124/share all-cash offer values NUVL at $10.6 billion premium.
• ↓Elevated leverage risk raises refinancing pressure amid rising rates.